Bodal Chemicals (BODALCHEM) - Q1 FY27 Earnings Impact & Multibagger Evaluation

Executive Summary

• As-of Date: 2026-08-05
• Current Price: ₹75.2 | Market Cap: ₹940 Cr
• Announcement: Q1 FY27 Earnings Presentation reporting 56% YoY revenue growth (₹715.2 Cr) and 218.7% YoY PAT growth (₹30.4 Cr).
• Verdict: POSSIBLE (Score: 62/100)

1. Earnings Turnaround & Ramp-Aware Analysis

Financial Acceleration Math

• Historical Baseline: FY26 Revenue was ₹2,012.7 Cr, PAT was ₹47.5 Cr (EPS ₹3.80).
• Q1 FY27 Performance:
• Revenue: ₹715.2 Cr vs ₹454.2 Cr in Q1 FY26 (+57.5% YoY).
• PAT: ₹30.4 Cr vs ₹9.53 Cr in Q1 FY26 (+218.7% YoY).
• Q1 FY27 single-quarter PAT (₹30.4 Cr) represents 64% of full-year FY26 PAT.
• Trailing 4-Quarter (TTM) Trajectory post-Q1 FY27:
• Q2 FY26: ₹6.0 Cr | Q3 FY26: ₹0.0 Cr | Q4 FY26: ₹32.0 Cr | Q1 FY27: ₹30.4 Cr
• TTM PAT = ₹68.4 Cr | TTM EPS = ₹5.48 (vs pre-announcement TTM EPS of ₹3.80).
• Trailing P/E drops instantly from 19.8x to 13.7x.
• Annualized Run-Rate:
• Annualized Revenue: ₹2,860 Cr (+42% over FY26).
• Annualized PAT: ₹121.6 Cr -> Annualized EPS: ~₹9.75.
• Forward P/E on annualized run-rate = 7.7x.

Operational Drivers

1. Saykha Facility Contribution: The newly commissioned Benzene downstream division at Saykha has begun commercial sales, providing top-line scale and operating leverage.
2. Subsidiary Momentum: Sener Boya (Turkey) reported +41% revenue growth with ₹2.2 Cr PAT.
3. Pricing Power: EBITDA margin held at 10.5% despite crude-linked raw material inflation, demonstrating effective cost pass-through.

2. Industry Context & Quality Assessment

• Industry: Dyes, Pigments & Basic Chemicals (Capital Intensity: MEDIUM, Expected CAGR: ~8.5%).
• Quality Gate Status: FAILED (Trailing ROCE at 7.0%, Debt at ₹813 Cr against Net Worth of ₹1,198 Cr, D/E 0.68).
• SEPA Grade: C (Improving from D). Trailing capital efficiency is suppressed due to prolonged capex gestation at Saykha. While operational turnaround is sharp, leverage prevents an immediate upgrade to Grade B.

3. Valuation Scenarios (12-24 Month Horizon)

Base Case: +65% Upside (Target Price: ₹124)

• Assumptions: FY27 Revenue reaches ₹2,650 Cr with PAT of ₹105 Cr (EPS ₹8.42) as Saykha continues steady utilization. P/E multiple re-rates moderately to 14.7x on sustained profitability and initial debt deleveraging.

Bull Case: +115% Upside (Target Price: ₹162)

• Assumptions: FY27/FY28 PAT expands to ₹130 Cr (EPS ₹10.42) driven by peak Saykha utilization, chemical sector tailwinds, and ROCE expansion above 13%. P/E multiple re-rates to 15.5x.

Bear Case: -25% Downside (Target Price: ₹56)

• Assumptions: Crude oil shock pushes raw material costs above 60% of revenue, compressing OPM back to 6-7%. Annual PAT contracts to ₹40 Cr (EPS ₹3.21) with P/E compressing to 17.5x.

4. Conclusion & Rationale

Bodal Chemicals demonstrates a classic cyclical operational turnaround driven by new production capacity (Saykha) coming online after years of capex. The stock trades at an attractive ~7.7x annualized forward P/E. However, high balance sheet leverage (₹813 Cr debt) and sensitivity to volatile crude prices prevent a 'STRONG_CANDIDATE' classification, capping the verdict at POSSIBLE.